康辰药业：KC1086完成I期临床试验首例受试者入组

Core Viewpoint - The company has successfully initiated the first subject enrollment for the Phase I clinical study of KC1086, a novel small molecule inhibitor targeting KAT6, aimed at treating advanced recurrent or metastatic solid tumors [1] Group 1 - The company announced the completion of the first subject enrollment for the clinical study titled "Evaluation of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of KC1086 in Patients with Advanced Recurrent or Metastatic Solid Tumors" [1] - KC1086 is characterized as a potent and highly selective small molecule inhibitor of lysine acetyltransferase 6 (KAT6) [1] - The intended use of KC1086 is for the treatment of advanced recurrent or metastatic solid tumors [1]